Novartis Vaccines & Dgnstcs - MA Middlesex, Cambridge 02139

Novartis Vaccines & Dgnstcs entered the industry of in 0 and has grown to employ 1 to 4 people, generating an annual revenue of Unknown. The NAICS classifies this business under the code 5417112, which describes it as a . For further clarification, the SIC classifies this business under the code 2834 and described it as a . The business provides service to the BOTH market.

To acquire more information, please contact Andrin Oswald, Chief Executive Officer by calling (617) 871-7000 during business hours. You can also write to the business’ Single Location at 350 Massachusetts Avenue # 200, Cambridge, Massachusetts MA 02139. You can also visit the company’s website at novartisvaccines.com. View this business’ social media profiles on Twitter or on Facebbok .

Company: Novartis Vaccines & Dgnstcs
Representative: Andrin Oswald, Chief Executive Officer
Place of Business: 350 Massachusetts Avenue # 200, Cambridge, MA 02139
Contact Number: (617) 871-7000
Website: novartisvaccines.com
Type of Service:
SIC Number: 2834
NAICS Number: 5417112
Locality: Single Location
Market Type: B2B & B2C
Income/Year: Unknown
Laborers: 1 to 4
Share This Company:

Novartis Vaccines & Dgnstcs is a company operating from Middlesex, Massachusetts providing professional and relevant BOTH variables. It was founded in 0 and registered with the SIC code 2834 as , and with the NAICS code 5417112 as .

With a current employee count of 1 to 4, Novartis Vaccines & Dgnstcs has gone to report making Unknown per annum on its journey towards growth. This company invites you to contact its representative Andrin Oswald, Chief Executive Officer at (617) 871-7000 for related queries, or to locate its Single Location using the coordinates 42.362716,-71.099264.

The Single Location can also be found at the street address 350 Massachusetts Avenue # 200 in Cambridge, Massachusetts 02139 and can be engaged online through the company website at novartisvaccines.com, the company Twitter , and Facebook page .